Related Experiment Video
Updated: Jun 11, 2026
11:17
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
Second-line chemotherapy for small-cell lung cancer (SCLC)
Young Hak Kim1, Michiaki Mishima
1Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan. ekim@kuhp.kyoto-u.ac.jp
Cancer Treatment Reviews
|June 29, 2010
Summary
Small-cell lung cancer (SCLC) often relapses after initial chemotherapy. Salvage chemotherapy effectiveness varies, with limited options for refractory cases, highlighting the need for better treatments.
Area of Science:
- Oncology
- Medical Research
Background:
- Small-cell lung cancer (SCLC) initially responds well to chemotherapy but frequently relapses.
- Salvage chemotherapy is crucial for relapsed SCLC, with distinct outcomes for sensitive versus refractory disease.
Purpose of the Study:
- To review current salvage chemotherapy strategies for relapsed small-cell lung cancer.
- To highlight the limited efficacy of existing treatments and the need for novel therapeutic approaches.
Main Methods:
- Review of clinical trials and approved therapies for relapsed SCLC.
- Analysis of treatment responses based on relapse sensitivity (sensitive vs. refractory).
Main Results:
- Topotecan is the only FDA-approved drug for relapsed SCLC and is a common second-line treatment.
- Amrubicin shows promising antitumor activity and is a potential therapeutic option.
- Targeted agents have not proven effective in SCLC treatment.
Conclusions:
- Relapsed SCLC, particularly refractory cases, presents a significant clinical challenge with limited effective salvage options.
- Further research into the molecular mechanisms of SCLC is essential for developing more effective targeted therapies.
